Principal Investigator’s Assurance Statement:
I understand my institution’s policies concerning research involving human subjects and the IRB’s policies for protection of
human subjects. I will:
protect the rights, safety and welfare of the subjects involved in this research
ensure research is conducted in an ethical manner and in accordance with all laws, regulations, or policies
applicable to the protection for human research subjects and requirements and determinations of the IRB
personally conduct or oversee those who conduct this research
supervise study personnel to whom tasks are delegated. Ensure that study personnel: 1) are qualified by training
and experience and licensure to perform study-related tasks that have been delegated to them; 2) have an
adequate understanding of the research; and 3) follow the IRB-approved protocol, including the recruitment and
consent procedures described in the protocol summary
ensure that study subjects are provided with: 1) reasonable medical care for any adverse events, including clinically
significant laboratory values, related to the research; 2) a qualified contact to answer questions or provide care
during the conduct of the research; and 3) the study plan is followed, such as inclusion/exclusion criteria, safety
assessments, safety monitoring and reporting of unanticipated problems, and procedures to protect privacy of
subjects and confidentiality of identifiable data, in order to minimize risks to subjects
obtain, document, and maintain records of informed consent from each subject or when approved by the IRB the
subject’s legally authorized representative using the consent document(s) approved by the IRB
conduct the research in accordance with the protocol approved by the IRB
initiate changes in the research, including the approved consent form(s), only after IRB approval, except where
necessary to eliminate apparent immediate hazards to subjects
report promptly to the IRB and to the subjects, any significant findings or new information that becomes known in
the course of the research that might change the risk of or justification for the research or may otherwise affect the
willingness of subjects to participate or to continue to participate in the research
report promptly to the IRB, any unanticipated problems involving risks to subjects or others in research
operate within the parameters that have been defined in the authorization portion of the consent regarding
Protected Health Information (PHI)
comply with all applicable FDA regulations, including the Good Clinical Practices Guidelines, and fulfill all
investigator responsibilities (or investigator-sponsor responsibilities, where appropriate), including those described
at 21 CFR 312 & 812
control drugs, biological products, and devices used for research purposes
submit a progress report for continuing review prior to expiration of IRB approval in accordance with UTHSCSA
Policy;
halt all research activities should IRB approval lapse, until the IRB re-approves the research or until special
permission is obtained from the IRB to continue previously enrolled subjects if determined to be in their best
interests to do so
promptly submit a final report when the research has been completed or is being closed out prior to completion
maintain adequate and accurate research records in accordance with institutional and, when applicable, the
sponsor or FDA requirements